Editorial: Community series in immunotherapy and small molecule inhibitors as combinational cancer therapeutics, volume II

作者
Mohd Wajid Ali Khan,Subhash Kumar Tripathi,Saravanan Rajendrasozhan
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:16: 1729774-1729774
标识
DOI:10.3389/fimmu.2025.1729774
摘要

Development and innovation of novel therapies for advanced cancer are based on conventional treatments such as radiotherapies and chemotherapies which lead a diverse array of immune responses. Wang et al. (2024) showed evidence that radiotherapy (RT) can function as an in-situ vaccine. It induces immunogenic cell death (ICD) releasing tumor antigens and damage-associated molecular patterns (DAMPs) that may initiate the activation of immune cells such as dendritic cells. Crucially, by causing DNA damage, RT activates the cGAS (Cyclic GMP-AMP synthase)-STING (Stimulator of interferon genes) pathway, leading to type I interferon production and inducing robust T-cell response. This transformation of the tumor immune microenvironment (TIME) from an immunosuppressive state to an immunologically active narrates the physiological phenomenon for the remarkable a systemic tumor response, where localized irradiation results in the regression of metastatic lesions outside the radiation field. Whereas the same biological processes can induce immunosuppression. RT can upregulate checkpoint proteins like PD-L1, promote the expansion of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and cause systemic lymphopenia, thereby counteracting its own immunostimulatory effects. Thus, ensures that RT is not a passive partner but an active immune modulator. The clinical challenge, therefore, is to strategically harness its immunostimulatory potential while reducing its suppressive effect. This can effectively be achieved via combination with immune checkpoint inhibitors (ICIs) Wang et al. (2024).In an extensive study on advanced Non-Small Cell Lung Cancer (NSCLC) by Wang et al. 2024 showed that pembrolizumab with radiotherapy treatment enhanced the patient conditions and lead to improved progression-free survival (PFS) and overall survival (OS) compared to pembrolizumab alone, with notably enhanced distant tumor response rates. The combinational therapeutics lend significant effect on solid tumor treatments. A meta-analysis of phase III clinical trials conducted by Zhang et al. (2024) analysed the role of ICIs as first-line standard therapy for recurrent or advanced cervical cancer. Overall outcome of the study exhibited improvements in both progression-free survival (HR 0.67) and overall survival (HR 0.66) with ICI-based treatments compared to single therapeutic treatments. The positive outcome was observed in patients with higher expression of PD-L1 in tumors and those with histology of squamous carcinoma. Whereas the combination of ICIs with conventional therapies was associated with slight increase in adverse events (AVs) relative to standard therapy alone. These findings emphasize the importance of careful patient monitoring during combination therapy. This also shed light for the need of thorough assessment of toxicity risks before adopting such treatment strategies in clinical practice.In a retrospective study, Wang et al. (2024) investigated the efficacy of combining the antiangiogenic agent anlotinib with immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy to improve outcomes in patients with non-small cell lung cancer (NSCLC). The triple combination therapy (AIC: anlotinib, ICI, and chemotherapy) achieved a median progression-free survival of 7.76 months, which was significantly longer by 2.33 months than that observed with the combination of ICIs and chemotherapy alone. These findings proved the significant role of adding anti-angiogenic agents into combination treatment regimens. Notably, even the two-drug combination of anlotinib and chemotherapy demonstrated superior progressionfree survival compared with the ICI-chemotherapy regimen. These findings strongly suggest that for later-line NSCLC patients, the addition of an anti-angiogenic agent is critical to delaying disease progression. Furthermore, the authors reported that the overall risks and toxicities were tolerable and can be controlled. Although the study included small number of sample sizes with single center collection, the study showed the potential of triple therapy as an effective treatment option for NSCLC patients who have not responded to standard conventional treatments. Further randomized controlled trials are warranted to validate these findings and confirm the efficacy and safety of this therapeutic approach.Li et al., (2024) performed a retrospective study and compared the effectiveness of targeted immunotherapy vs targeted therapy alone in the third-line or beyond setting for microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients (n=71) to help identify the beneficial population of combined targeted-immunotherapy. Out of a total of 71 subjects, 31 received targeted therapies alone (TT group), and 40 received combinations of targeted therapy and immunotherapy (TI group). The outcome of the study was that combination therapy improved response rates (20% vs. 3.2%) and controlled disease (82.5% vs. 58.1%), with longer median progression-free survival (4.6 vs. 4.1 months). The most significant outcome of the combinational targeted immunotherapy was observed in patients with lung metastasis alone. These findings suggest that targeted immunotherapy combinations can enhance efficacy in selected MSS mCRC patients. Further studies with larger patient cohorts are still necessary to strengthen reliability and validity.In another retrospective study involving 71 patients, Zhao et al. (2024) investigated whether baseline lymphocyte counts could help identify which hepatocellular carcinoma (HCC) patients would benefit from targeted combination immune therapy. The study showed that both progression-free survival (PFS) and overall survival (OS) improved (p = 0.058 and p = 0.077, respectively) in patients receiving combination therapy with tyrosine kinase inhibitors (TKIs) and PD-1 inhibitors. Notably, patients with high peripheral blood lymphocytes count (PBLC) exhibited better OS and PFS as compared to the cancer patients with low absolute PBLC. These results highlight PBLC could be a routine blood measure which can be use as potential biomarker to identify HCC patients most likely to benefit from TKI and PD-1-based combination therapy.Implementing lymphocyte count as a stratification or decision-making tool could optimize precision therapy and minimize unnecessary toxicity and cost. Additional trials, such as CARES-310 (camrelizumab plus apatinib) and HIMALAYA (durvalumab plus tremelimumab), also showed encouraging efficacy, with the latter achieving an ORR of 20.1%, median PFS of 3.8 months, and median OS of 16.4 months in unresectable HCC.ICIs for the treatment of unresectable advanced HCC patients. In addition, there is also the phase II study of TACE in combination with nivolumab for intermediate-stage HCC (IMMUTACE) and the phase III LEAP-012 (NCT04246177) study of TACE in combination with lenvatinib and pembrolizumab for intermediate stage HCC, which also exhibited better results. However, this rapidly expanding combinational therapeutics is include significant challenges, including the need to identify optimal biomarkers for patient selection, manage unique immune-related adverse events, overcome primary and acquired resistance, and define the most effective sequences and combinations within an increasingly complex treatment landscape. The future of HCC therapy lies in deepening our understanding of the tumor-immune environment to guide these sophisticated, personalized combination approaches.A meta-analysis study by Zhao et al. (2024) evaluates the safety and efficacy on combining concurrent chemoradiotherapy (CCRT) with ICIs in locally advanced cervical cancer (LACC).The combined data suggests that together, CCRT and ICIs may improve objective response rates (ORR) compared to CCRT alone, with an improved disease free survival trend. Whilst these findings are promising, the evidence remains limited, and hence, long-term outcomes and overall safety require further investigation. This study emphasizes the potential of combining immunotherapy with standard LACC treatment to enhance therapeutic efficacy.A systematic review and meta-analysis study evaluated the efficacy and safety of anlotinib in advanced digestive system neoplasms (DSNs). Twenty clinical trials which include 1613 patients, exhibited anlotinib combined with conventional cancer treatments significantly improved shortterm outcomes. Patients' overall survival time increased by 6-month. This study exhibited that the combinational therapy increased the higher incidence of adverse events including hypertension, proteinuria, fatigue, and gastrointestinal disturbances. There were no treatment-related deaths occurred. Subgroup analysis indicated a relatively less effect in advanced gastric cancer. These findings demonstrate anlotinib with other combinational interventions proved as promising therapeutics in DSN treatment (Zhou et al., (2024)). Furthermore, there is more careful risk-benefit assessment needed and further studies to define long-term efficacy and optimal patient selection. Predictive models are essential for several reasons. First, they move clinical practice beyond population-level evidence, these highly important for establishing efficacy. Heterogeneity of treatment effects provide individual patient responses to the treatment may vary. The therapy that offers a modest survival benefit on one patient and entirely ineffective for another. By including variables such as tumor genomics (e.g., PD-L1 status, mutational burden), clinical parameters (e.g., lactate dehydrogenase levels, sites of metastasis), host factors (e.g., baseline lymphocyte count as highlighted by Zhao et al. (2024) in HCC), and specific treatment conditions, these models can classify patients into subgroups most likely to derive benefit. Second, these models are crucial for risk mitigation. As starkly illustrated by the case report of sintilimab-induced agranulocytosis Qin et al. (2024), the potent activation of the immune system by ICIs carries the risk of severe and unpredictable toxicities. Predictive modeling is not solely about predicting efficacy; it is equally about identifying patients at high risk for immune-related adverse events (irAEs). A model that could flag a patient's predisposition to hematological toxicity, for instance, would allow for enhanced monitoring and preemptive management, thereby improving safety.The predicted future of these treatment tools relies on the development of dynamic treatment plan designed by AI, using clinical data derived from the electronic health records of diverse range of patients, multi-omics profiling, and even digital biomarkers. This continuous leaning AI-designed treatment plan will the best use of available therapy and eventually create a 'digital treatment planner' that can simulate the possible therapeutic outcome and side effects of various combinations of drug treatment for a particular patient. The data-driven treatment plan can ensure the individual-specific cancer care and thereby maximize the therapeutic potential of combination of drugs with minimal side-effects. Qin et al. (2024) reported an immune-related adverse events (irAEs) caused by a cancer immunotherapy drug, sintilimab (anti-PD-1 Ab). Sintilimab induced agranulocytosis in a patient with non-small cell lung cancer, which highlight the unpredictable side-effects and limitations in ICI cancer therapy. Although, ICIs treatment is effective in cancer treatment, their mechanism of activating T-cells is primarily related to over-response of the immune system, leading to side effects like autoreactive immune responses, in this case causing life threatening condition by causing severely low levels of white blood cells called neutrophils. Distinguishing the side-effects of chemotherapy from irAEs is challenging and time consuming. To treat the sintilimab-induced agranulocytosis, a high-dose of corticosteroid was administered, which is not usually included in the standard cancer care. The irAEs poses a significant clinical management challenge as it counter-balance the therapeutic benefits of ICIs.The collective evidence confirms a new major shift in oncology, based on synergistic combinational therapies. We are moving decisively from the era of sequential, non-specific cytotoxic treatments to a synergistic era defined by rationally designed combination therapies that strategically harness and augment the host's immune system. The combination of immunotherapy along with chemotherapy, radiotherapy, targeted agents and/or localized treatments has become an effective clinical treatment strategy in treating various cancer, including NSCLC, breast cancer, HCC, and cervical cancer. This new frontier, however, is accompanied by numerous challenges that need to be addressed for tailoring proper cancer treatment. As our therapeutic regimen expands, the principal challenge is the lack of robust, predictive biomarkers to guide selection among numerous combination options.The promising findings regarding baseline lymphocyte counts in HCC and PD-L1 status in cervical cancer are initial steps; the future demands the discovery and validation of multi-analyte signatures that can predict both efficacy and toxicity for specific drug combinations.Optimizing treatment sequencing and timing has become crucial. The superior efficacy of neoadjuvant immunotherapy in some extent showed importance of treatment schedule. Choosing concurrent or sequential delivery in an optimal order of radiotherapy, chemotherapy, and immunotherapy is critical for maximizing synergistic potential and minimizing antagonistic effects.To achieve the greater clinical benefit of innovational therapies, the management of irAEs is essential, which can be achieved by developing standardized, preventive management protocols and predictive models for irAEs.Finally, the issue of 'easily access to everyone' must be focused on. The affordability of the multidrug combination treatment is a significant barrier to widespread clinical use. Drug price control, by the concomitant efforts of researchers, clinicians, and policymakers, is essential to prevent the disparity in cancer care. Looking forward for the future era of combinational therapeutics will be demonstrated by exploiting artificial intelligence and multi-omics data to create dynamic and individualized "digital treatment planners" based on clinical effeteness of the drugs with respect to the patient-specific factors.In conclusion, combinational treatment designed with multi-target approach on the tumor-immune ecosystem will be the future of standard cancer treatment. This promising therapeutic approach has the potential significantly improve quality of life and survivability of cancer patients, effectively transforming cancer into a more manageable disease.Keywords: cancer, immunotherapy, immune check point inhibitors, PD1/PD1-L, combinational therapeutics, digital treatment planners

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
nenshen完成签到,获得积分10
刚刚
Xiang123完成签到,获得积分10
刚刚
刚刚
lml发布了新的文献求助10
1秒前
成就自行车关注了科研通微信公众号
1秒前
金融完成签到,获得积分10
2秒前
Dong完成签到,获得积分10
2秒前
阳光男孩完成签到,获得积分10
2秒前
zzz完成签到,获得积分10
2秒前
王晴晴完成签到,获得积分10
3秒前
酷波er的应助被聪聪哥哥采纳,获得10
3秒前
lijiaoshou完成签到,获得积分10
3秒前
3秒前
沉默的怀绿完成签到,获得积分10
3秒前
abc37发布了新的文献求助10
3秒前
无奈的萍完成签到,获得积分10
3秒前
xixi发布了新的文献求助10
4秒前
天然完成签到,获得积分10
4秒前
4秒前
霸王丹完成签到,获得积分10
5秒前
斯文败类的应助被dddd采纳,获得10
5秒前
丘比特的应助被霁月采纳,获得10
5秒前
和树发布了新的文献求助10
6秒前
zww发布了新的文献求助10
6秒前
molihuakai的应助被霁月采纳,获得10
6秒前
molihuakai的应助被霁月采纳,获得10
6秒前
无辜小鸭子完成签到,获得积分10
6秒前
Ava的应助被霁月采纳,获得10
6秒前
星辰发布了新的文献求助10
6秒前
Blackmamba发布了新的文献求助10
6秒前
嘟噜嘟噜完成签到,获得积分10
6秒前
小二郎的应助被霁月采纳,获得10
6秒前
6秒前
睡醒了发布了新的文献求助10
6秒前
After发布了新的文献求助10
6秒前
海棠完成签到,获得积分10
7秒前
7秒前
JamesPei的应助被倦梦还采纳,获得10
7秒前
7秒前
Yingzi完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182743
求助须知:如何正确求助?哪些是违规求助? 9572114
关于积分的说明 21822835
捐赠科研通 7779324
什么是DOI,文献DOI怎么找? 3433718
关于科研通互助平台的介绍 2557891
邀请新用户注册赠送积分活动 2479803